Innate Pharma Files Routine 6-K Report on March 26, 2026
Ticker: IPHA · Form: 6-K · Filed: Mar 26, 2026 · CIK: 0001598599
Complexity: simple
Sentiment: neutral
Topics: regulatory-filing, compliance
TL;DR
**Innate Pharma's 6-K is a routine compliance filing, no big news here.**
AI Summary
Innate Pharma SA filed a 6-K report on March 26, 2026, indicating a routine foreign issuer report. This filing, with accession number 0001628280-26-021168, includes two documents: the 6-K itself and an EX-99.1 exhibit. For investors, this filing is a standard compliance update and doesn't contain new material financial or operational news, meaning it likely won't impact the stock price significantly.
Why It Matters
This filing is a standard compliance report for foreign issuers and does not contain new material information that would typically move the stock price.
Risk Assessment
Risk Level: low — This 6-K filing is a standard regulatory update and does not introduce new financial or operational risks.
Analyst Insight
Investors should recognize this as a standard regulatory update without new material information, suggesting no immediate action is required based solely on this filing.
Key Numbers
- 2026-03-26 — Filing Date (the date the 6-K report was filed)
- 2 — Number of Documents (the total number of documents included in the filing)
- 10437 — Size of 6-K document (the size in bytes of the main 6-K document)
- 179171 — Size of EX-99.1 document (the size in bytes of the exhibit EX-99.1 document)
Key Players & Entities
- Innate Pharma SA (company) — the filer of the 6-K report
- 0001598599 (company) — Innate Pharma SA's CIK number
- 0001628280-26-021168 (dollar_amount) — the SEC Accession No. for this filing
Forward-Looking Statements
- The stock price of Innate Pharma SA will remain stable following this routine 6-K filing. (Innate Pharma SA) — high confidence, target: 2026-03-27
FAQ
What is the purpose of a 6-K filing for Innate Pharma SA?
A 6-K filing is a 'Report of foreign issuer' under Rules 13a-16 and 15d-16, used by foreign private issuers like Innate Pharma SA to report material information to the SEC that is made public in their home country or filed with a foreign stock exchange.
When was this specific 6-K filing submitted and accepted by the SEC?
This 6-K filing was submitted and accepted on March 26, 2026, at 06:03:00.
How many documents are included in this 6-K submission, and what are their types?
There are two documents included: '1 6-K a2603266kincorporatediph.htm' which is the main 6-K document, and '2 EX-99.1 a200326exhibit991.htm' which is an exhibit.
What is Innate Pharma SA's CIK number and SIC code?
Innate Pharma SA's CIK number is 0001598599, and its SIC code is 2836, which stands for 'Biological Products, (No Diagnostic Substances)'.
Where is Innate Pharma SA's business and mailing address located?
Innate Pharma SA's business and mailing address is 117 AVENUE DE LUMINY BP 30191 MARSEILLE FRANCE France 13009.
Filing Stats: 269 words · 1 min read · ~1 pages · Grade level 10.1 · Accepted 2026-03-26 06:03:00
Filing Documents
- a2603266kincorporatediph.htm (6-K) — 10KB
- a200326exhibit991.htm (EX-99.1) — 175KB
- 0001628280-26-021168.txt ( ) — 187KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. INNATE PHARMA S.A. Date March 26, 2026 By s JONATHAN DICKINSON Name Jonathan Dickinson Title Chief Executive Officer